Author of

• 25940

  +

  P2.03 - Biology (Not CME Accredited Session) (ID 952)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall

  • 26962

    +

    P2.03-25 - Loss of Expression Rather Than Cytoplasmic Mislocalization of RUNX3 Predicts Worse Outcome in Non-Small Cell Lung Cancer (ID 12032)

    16:45 - 18:00  |  Author(s): Xiongwei Zheng
    • Abstract
    • Slides

    Background
    

    Functional inactivation of RUNX3 through epigenetic silencing was well-documented in many cancers. Added to gene mutation and promoter hypermethylation, cytoplasmic mislocalization was another major manifestation of RUNX3 dysfunction in malignancies like gastric cancer. We aimed to investigate whether NSCLC patients with different RUNX3 expression patterns would have differrent OS, and the associations of different patterns with clinicopathologic parameters and clinical outcome.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    Expressions of RUNX3 and Ki-67 were immunohistochemically detected in normal lung tissue (n=5) and surgically resected NSCLC patients (n=188). The optimal cutoff of RUNX3 was determined by X-tile software related to their survival. Apoptotic index in cancerous tissue was evaluated by TdT mediated dUTP-biotin nick end labelling (TUNEL) method. The prognostic significance of different expression patterns of RUNX3 was determined by means of Kaplan-Meier survival estimates and log-rank tests.

    4c3880bb027f159e801041b1021e88e8 Result
    

    Loss of RUNX3 expression in NSCLC was correlated with low cancerous apoptotic index (P<0.001), shorter OS and worse prognosis (P=0.0142), while no statistical difference of apoptotic index (P=0.73) or survival (P=0.3781) had been determined between patient subgroups with different localization of RUNX3 expression.

    

    

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    Loss of expression rather than cytoplasmic mislocalization of RUNX3 predicted worse outcome in NSCLC, which was quite different from what it manifested in other cancer types.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.